In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by α2-adrenoceptor antagonism

European Neuropsychopharmacology

Volumn 20, Issue 11, 2010, Pages 813-822

  Ortega, Jorge E ^a   Fernández Pastor, Begoña ^a   Callado, Luis F ^a   Meana, J Javier ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

2 Adrenoceptor; Locus coeruleus; Microdialysis; Noradrenaline; Prefrontal cortex

Indexed keywords

12 ETHYLSULFONYL 5,8,8A,9,10,11,12,12A,13,13A DECAHYDRO 3 METHOXY 6H ISOQUINO[2,1 G][1,6]NAPHTHYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR; CITALOPRAM; NORADRENALIN; REBOXETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; IN VIVO STUDY; LOCUS CERULEUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; BRAIN; CITALOPRAM; DRUG SYNERGISM; EXTRACELLULAR SPACE; LOCUS COERULEUS; MALE; MORPHOLINES; NOREPINEPHRINE; PREFRONTAL CORTEX; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77957020753     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.07.008     Document Type: Article

References (72)

1. 2-adrenoceptor antagonism. Bioorg. Med. Chem. 2007, 15:3649-3660.
2. 1A antagonists. Trends Neurosci. 1996, 19:378-383.
3. Ballesteros J., Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affect. Disord. 2004, 79:137-147.
4. Bandoh T., Hayashi M., Ino K., Takada S., Ushizawa D., Hoshi K. Acute effect of milnacipran on the relationship between the locus coeruleus noradrenergic and dorsal raphe serotonergic neuronal transmitters. Eur. Neuropsychopharmacol. 2004, 14:471-478.
5. Béïque J., de Montigny C., Blier P., Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in the rat. Neuropharmacology 2000, 39:1800-1812.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Brøsen K., Naranjo C.A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol. 2001, 11:275-283.
8. 2-adrenoceptor antagonist. Br. J. Pharmacol. 1993, 108:516-525.
9. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. 1998, 34:281-302.
10. 2a-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem. 1998, 70:1114-1123.
11. Cappiello A., McDougle C.J., Malison R.T., Heninger G.R., Price L.H. Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol. Psychiatry 1995, 38:765-767.
12. Cedarbaum J.M., Aghajanian G.K. Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique. J. Comp. Neurol. 1978, 178:1-16.
13. 1A receptors in human cerebral cortex. Eur. J. Pharmacol. 1989, 159:307-310.
14. 2-adrenoceptor antagonist and monoamine uptake inhibitor properties. J. Med. Chem. 2001, 44:787-805.
15. Dam J., Ryde L., Svejsø J., Lauge N., Lauritsen B., Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998, 31:48-54.
16. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 1987, 241:642-649.
17. Devoto P., Flore G., Pira L., Longu G., Gessa G.L. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur. J. Pharmacol. 2004, 487:105-111.
18. Dhir A., Kulkarni S.K. Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 2007, 80:239-243.
19. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 1998, 19:381-390.
20. 2-adrenoceptors. Eur. J. Pharmacol. 2002, 442:225-229.
21. Florin-Lechner S.M., Druhan J.P., Aston-Jones G., Valentino R.J. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 1996, 742:89-97.
22. García-Sevilla J.A., Guimón J., García-Vallejo P., Fuster M.J. Biochemical and functional evidence of supersensitive platelet α2-adrenoceptors in major affective disorder. Effect of long-term lithium carbonate treatment. Arch. Gen. Psychiatry 1986, 43:51-57.
23. 2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem. 1997, 69:2616-2619.
24. 2A-adrenoceptors. Mol. Psychiatry 2002, 7:755-767.
25. 2-Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat locus coeruleus neurons. Eur. J. Pharmacol. 2005, 517:51-58.
26. Haddjeri N., de Montigny C., Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system. Br. J. Pharmacol. 1997, 120:865-875.
27. Hannan N., Hamzah Z., Akinpeloye H.O., Meagher D. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J. Psychopharmacol. 2007, 21:161-164.
28. 3H]imipramine localization and relationship to serotonin transporter. J. Pharmacol. Exp. Ther. 1990, 252:410-418.
29. Hughes Z.A., Stanford S.C. Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br. J. Pharmacol. 1998, 124:1141-1148.
30. 2-adrenoceptors in the prefrontal cortex. Br. J. Pharmacol. 2001, 132:183-188.
31. 2-adrenoceptor blockade. Biol. Psychiatry 1999, 46:766-774.
32. Maes M., Libbrecht I., van Hunsel F., Campens D., Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 1999, 19:177-182.
33. 2-adrenoceptor subtype located in rat locus coeruleus that modulates cortical noradrenaline release in vivo. Eur. J. Pharmacol. 1999, 379:53-57.
34. 2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 1998, 71:790-798.
35. Mateo Y., Ruiz-Ortega J.A., Pineda J., Ugedo L., Meana J.J. Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo. Neuropharmacology 2000, 39:2036-2043.
36. 2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br. J. Pharmacol. 2001, 133:1362-1370.
37. Mavroidis M.L., Kanter D.R., Greenblum D.N., Garver D.L. Adrenergic-receptor desensitization and course of clinical improvement with desipramine treatment. Psychopharmacology 1984, 83:295-296.
38. 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J. Neural Transm. 1987, 70:377-381.
39. 1A receptors in the rat brain. Eur. J. Pharmacol. 1996, 312:385-388.
40. 2-Adrenoceptors mediate the acute inhibitory effect of fluoxetine on locus coeruleus noradrenergic neurons. Neuropharmacology 2009, 56:1068-1073.
41. 2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000, 12:1079-1095.
42. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther. 1993, 264:1187-1197.
43. 2A adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358:197-206.
44. 2-adrenoceptors in the locus coeruleus in major depression. Biol. Psychiatry 2003, 53:315-323.
45. Owens M.J., Knight D.L., Nemeroff C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol. Psychiatry 2000, 47:842-845.
46. Pallanti S., Quercioli L., Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J. Clin. Psychiatry 2004, 65:1394-1399.
47. 2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology 2005, 30:1048-1055.
48. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, New York.
49. 2 adrenoreceptors in depressive illness. Life Sci. 1986, 39:1589-1616.
50. Portella M.J., de Diego-Adelino J., Puigdemont D., Pérez-Egea R., Álvarez E., Artigas F., Pérez V. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur. Neuropsychopharmacol. 2009, 19:516-519.
51. Pudovkina O.L., Cremers T.I., Westerink B.H. The interaction between the locus coeruleus and dorsal raphe nucleus studied with dual-probe microdialysis. Eur. J. Pharmacol. 2002, 445:37-42.
52. Redfern W.S., MacKinnon A.C., Brown C.M., Martin A.B., Kilpatrick A.T., Clague R.U., Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br. J. Pharmacol. 1993, 108:526-533.
53. Rizk P., Salazar J., Raisman-Vozari R., Marien M., Ruberg M., Colpaert F., Debeir T. The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology 2006, 31:1146-1157.
54. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br. J. Pharmacol. 1999, 128:1332-1338.
55. 2-adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 363:66-72.
56. Sanacora G., Berman R.M., Cappiello A., Oren D.A., Kugaya A., Liu N., Gueorguieva R., Fasula D., Charney D.S. Addition of the α2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 2004, 29:1166-1171.
57. Sánchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 1999, 19:467-489.
58. 1D receptors. Eur. J. Pharmacol. 1991, 196:213-216.
59. Singewald N., Kaehler S., Hemeida R., Philippu A. Release of serotonin in the rat locus coeruleus: effects of cardiovascular, stressful and noxious stimuli. Eur. J. Neurosci. 1997, 9:556-562.
60. Sjöholm B., Lahdesmaki J., Pyykko K., Hillila M., Scheinin M. Non-adrenergic binding of [3H]atipamezole in rat kidney-regional distribution and comparison to α2-adrenoceptors. Br. J. Pharmacol. 1999, 128:1215-1222.
61. Svensson T.H., Bunney B.S., Aghajanian G.K. Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res. 1975, 92:291-306.
62. Szabo S.T., Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001, 922:9-20.
63. Szabo S.T., de Montigny C., Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br. J. Pharmacol. 1999, 126:568-571.
64. Szabo S.T., de Montigny C., Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol. 2000, 3:1-11.
65. Taber M.T., Kinney G.G., Pieschl R.L., Yocca F.D., Gribkoff V.K. Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections. Synapse 2000, 38:17-26.
66. 3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 1992, 260:427-436.
67. Thomas D.N., Holman R.B. A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J. Neurochem. 1991, 56:1741-1746.
68. Thomas D.N., Nutt D.J., Holman R.B. Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. J. Psychopharmacol. 1998, 12:366-370.
69. Winter J.C., Rabin R.A. Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J. Pharmacol. Exp. Ther. 1992, 263:682-689.
70. Wong E.H., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry 2000, 47:818-829.
71. 2-adrenoceptors. Br. J. Pharmacol. 1999, 128:659-666.
72. Yanpallewar S.U., Fernandes K., Marathe S.V., Vadodaria K.C., Jhaveri D., Rommelfanger K., Ladiwala U., Jha S., Muthig V., Hein L., Bartlett P., Weinshenker D., Vaidya V.A. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J. Neurosci. 2010, 30:1096-1109.